

## REMARKS

By the present amendment, applicants have made the following amendments to the claims:

- (i) canceled Claim 2;
- (ii) limited the ACE inhibitor in Claims 1, 3-5, and 21 to quinapril;
- (iii) removed the language "wherein the formation of an internal cyclization product, and/or ester hydrolysis product, and/or oxidation product, has been reduced or eliminated" from the independent claims (Claims 1 and 21); and
- (iv) corrected the dependency of Claim 16.

Therefore, the claims remaining for consideration by the Examiner are Claims 1, 3-10 and 14-21.


The Examiner states that applicants have demonstrated unexpected results where the ACE inhibitor is quinapril, and thus, applicants claims would be allowable if limited to quinapril.

In response, applicants have limited the ACE inhibitor in Claims 1, 3-5, and 21 to quinapril or a pharmaceutical acceptable salt thereof.

Applicants respectfully request the Examiner to enter applicants' amendment and pass the application to issuance. If the Examiner has any questions concerning this amendment, the Examiner is encouraged to contact the undersigned.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 430  
East Hanover, NJ 07936-1080  
(862) 778-7945

  
\_\_\_\_\_  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Date: September 20, 2004